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Background: Sleep-related Cheyne–Stokes (CS) respiration is a known phenomenon in chronic heart failure (CHF). We aimed to study the
prevalence, clinical correlates, risk factors and prognostic relevance of daytime CS, as well as its relation with neurohormonal derangement.
Methods: One hundred forty seven CHF patients with left ventricular systolic dysfunction (age: 64±12 years, ejection fraction, EF, 31±8%,
mean±SD) underwent morning polygraphic recording, in addition to comprehensive clinical and neurohormonal evaluation.
Results: Daytime CSwas detected in 87 patients (59%), and associated with worse NYHA class (2.6±0.7 vs 2.2±0.8, Pb0.05), lower EF (29±
8 vs 33±8%, Pb0.05), peak oxygen consumption (11.3±8.3 vs 13.4±4mL/min/kg, Pb0.05), resting carbon dioxide level (33.1±4.2 vs 37.9±
3.8 mm Hg, Pb0.001), higher norepinephrine [588 (395–939) vs (331–681) ng/L, median (interquartile range) Pb0.01] and natriuretic
peptides [ANP: 136 (57–230) vs 66 (18–103); BNP: 284 (99–510) vs 64 (21–202); NT-proBNP: 2575 (814–3320) vs 448 (147–1599) ng/L,
all: Pb0.001]. At univariate analysis, CS risk factors were age, EF, carbon dioxide, creatinine, norepinephrine, natriuretic peptides, whereas age
andNT-proBNP level were the onlymultivariate predictors. On a 33-month follow-up, CS resulted among univariate predictors of cardiac death,
NT-proBNP emerging as the only variable at multivariate analysis.
Conclusions: Daytime CS is frequent in CHF and is correlated with clinical severity, neurohormonal derangement, particularly of NT-
proBNP, and long-term prognosis.
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Periodic breathing frequently occurs in patients with
chronic heart failure (CHF), and is characterized by
Cheyne–Stokes respiration (CS) either with central hypopneas
or apneas alternating with hyperventilation [1]. CS has been⁎ Corresponding author. G. Monasterio Foundation, CNR-Regione Toscana,
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doi:10.1016/j.ijcard.2008.06.028more commonly detected at nighttime as sleep-related, in
association with oxyhemoglobin desaturation, frequent arou-
sals, sleep fragmentation [2], altered quality of life [3], and
sympathetic overactivation [4–5], which may contribute to
deterioration of cardiac function and reduced survival [6,7].
Few studies in small subsets have evaluated CS at daytime
[4,8] in awake patients too, indicating a poor prognosis [9].
Neurohormonal derangement, involving activation of
sympathetic, renin–angiotensin–aldosterone systems, and
cardiac natriuretic peptide systems is a hallmark of CHF
[10–11]. Plasma levels of brain natriuretic peptide (BNP)
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hormone (NT-proBNP), in particular, have been recognized
as diagnostic and prognostic markers in CHF patients [12].
Whereas determinants of central sleep apneas have
already been described [13], risk factors and clinical
correlates of daytime CS remain unknown. Furthermore,
the possible association of daytime CS and neurohormonal
activation system has not been fully investigated. The aim of
the present study was to evaluate prevalence and risk factors
for daytime CS in CHF patients.
2. Methods
2.1. Patients
From September 2002 to November 2005, we selected
184 consecutive CHF patients with depressed left ventricular
ejection fraction (EF, b45%) at echocardiography. Exclusion
criteria were acute coronary syndrome within the preceding
6 months, severe chronic obstructive pulmonary disease,
severe renal impairment (serum creatinine level N2.5 mg/dl),
use of morphine, benzodiazepines, any psychotropic drug or
theophilline derivatives. In order to focus on central
hypopneas and apneas, additional exclusion criteria were
also chosen, such as obesity (body mass index N30 kg/m2)
and history of snoring and upper airways obstruction. Of the
184 patients, 37 did not fulfill these criteria, leaving 147
patients for enrollment [(118 males and 29 females, mean
age 64±12 years, body mass index 25±2.7 kg/m2, EF 31±
8%, with ischaemic (46%), idiopathic (39%) or secondary
(15%) cardiomyopathy (8% with hypertensive cardiomyo-
pathy, and 7% with valvular disease), NYHA class I–II 65%,
III–IV 35%)]. All patients were on optimal pharmacological
treatment (82%: furosemide, 73%: carvedilol/bisoprolol,
84%: angiotensin-converting enzyme inhibitors/angioten-
sin-receptor blockers, 59%: spironolactone); 12 patients
(9%) had previously received cardiac resynchronisation
therapy.
The study was approved by the Institute's Ethical
Committee and informed consent was obtained from all
patients.
2.2. Cardiopulmonary exercise test, echocardiographic
study and plasma assays
A symptom-limited cardiopulmonary test was performed
on a bicycle ergometer using a ramp protocol with
increments of 10 W/min (Vmax, Sensormedics, USA). All
echocardiographic studies were performed by the same
physician. Blood samples were drawn at 8 a.m. from an
antecubital vein, after a 20-minute supine rest. Atrial
natriuretic peptide (ANP), BNP, plasma catecholamines,
plasma renin activity (PRA), aldosterone, and thyroid
hormones were assayed as described elsewhere [10]; NT-
proBNP was measured with an automated electrochemilu-
minescent immunoassay (Roche diagnostics, Germany).2.3. Polygraphy
During the same morning, all subjects, in the supine
position, were asked to relax without falling asleep, and
during spontaneous breathing were evaluated for a 20-
minute period, with a previously validated technique [4].
During each examination, we recorded a II electrocardio-
graphic lead, chest and abdominal movement by electrical
inductance, oronasal airflow, beat-to-beat blood pressure
(Colin® tonometry, San Antonio, TX, USA), oxygen
saturation (Pulse Oxymeter Pulsox-7, Minolta®) and end-
tidal pCO2 signal (PETCO2, Cosmoplus®, Novametrics).
Data were digitized (300 sample/s), and stored on a personal
computer. CS was defined either by the occurrence of cyclic
episodes of apnea (cessation of flow and respiratory
movements for ≥10 s) [5] or of hypopnea (reduction in
the tidal volume greater than 50%, lasting ≥10 s, followed
by a reduction in oxygen saturation of ≥4%), followed by
hyperpnoea.
Fifty-three patients (36%) also underwent, within 24 h, a
nocturnal continuous polysomnographic recording. An
apnea–hypopnea index (defined as the number of apneas
and hypopneas per hour) ≥20 was used as arbitrary cut-off
to define relevant nighttime CS. Main clinical characteristics
of patients receiving nocturnal recording were similar to
those of the overall population: 41 males and 12 females,
mean age 65±1 years, body mass index 25±0.3 kg/m2, EF
31±1%, with ischaemic (44%), idiopathic (38%) or
secondary (18%) cardiomyopathy, NYHA class I–II 63%,
III–IV 37%.
2.4. Follow-up
Follow-up started at the time of hospital admission and
continued until study termination. Independent interviewers
obtained information directly from patients, relatives, or
Institute cardiologists or general practitioners, regarding the
date of death, between the time of discharge and September
2007. The primary end-point was cardiac death, including
pump failure (defined as a death resulting from multiorgan
failure caused by heart failure progression) and sudden death
(defined as a witnessed cardiac arrest, death within 1 h after
the onset of acute symptoms, or an unexpected death in a
patient known to have been well within the previous 24 h).
Information about time and cause of death was obtained
from death certificates, post-mortem reports and family
doctors. The individual follow-up ended with death or with
cardiac surgery (ventricular assist device implantation, heart
transplantation). No patient was lost to follow-up.
2.5. Statistical analysis
Statistical analysis was carried out using SPSS 12.0
(SPSS inc., Chicago, Il, USA). Due to the skewed
distribution of BNP, NT-proBNP, norepinephrine, PRA and
aldosterone, their natural logarithm was used for statistical
Fig. 1. Top-down: Time-course of oxygen saturation (SpO2), airflow, combined respiratory signal (Sum) from chest and abdominal inductance recordings, RR
interval (RR) in a 62-year old patient with ischaemic cardiomyopathy and daytime Cheyne–Stokes respiration are shown.
Fig. 2. Comparison of plasma concentration of atrial natriuretic peptide
(ANP), brain natriuretic peptide (BNP), amino-terminal fragment of
probrain natriuretic peptide (NT-proBNP), and norepinephrine (NEPI) in
patients with Cheyne–Stokes respiration (CS) and patients with normal
breathing; ⁎Pb0.01.
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when needed. Groups were compared for frequencies or
categorical data (i.e., NYHA class) using the chi-squared test.
Differences between groups in continuous variables were
evaluated by the t-test for independent samples; differences
between groups in categorical variables were evaluated by
chi-square or Fischer exact test. Univariate and multiple
logistic regression analyses were used to examine the
association between several baseline clinical and neurohor-
monal variables and the presence of daytime CS occurrence.
The candidate independent variables used for analysing risk
factors for CS were selected on the basis of the strength of
association with CS presence shown by previous studies in
similar populations: body mass index, NYHA functional
class, EF, presence of atrial fibrillation, presence of a paced
cardiac rhythm, age, gender, mean resting PETCO2 during
wakefulness, medication, and cause of CHF, as previously
described for sleep-related CS [13]. In addition, we have
considered serum creatinine level, arterial pressure, left
atrium area, maximum workload and peak oxygen consump-
tion at cardiopulmonary test, plasma level of ANP, BNP, NT-
proBNP, norepinephrine, renin activity, and aldosterone.
Univariate predictors (age, ejection fraction, serum creati-
nine, NYHA functional class, peak oxygen consumption at
cardiopulmonary test, plasma level of BNP, NT-proBNP and
norepinephrine) were then considered for multivariate Cox
proportional hazard regression analysis, with the exception of
plasma BNP which, although closely related to NT-proBNP
secretion, had a lower level of significance.
The predictive power of variables was quantified using
receiver operating characteristic curves (ROC). A difference
in the area under the curve (AUC) defined the increment in
predictive power between different models. The statisticalsignificance of differences in AUC from the line of “no
information” and between different curves was evaluated
with Mann–Whitney U-Statistics.
Survival curves were analysed using the Kaplan–Meier
estimate and comparisons were made with log-rank test. In
addition, Cox proportional hazards model was used to
identify significant prognostic. The relative risk for each
independent variable in the hazard equation was directly
proportional to the risk brought by that variable to the model.
All hazard ratios are presented with 95% confidence
intervals and all P values are two-sided.
The candidate variables chosen for survival analysis have
already been linked to long-term survival in previous studies
conducted in similar populations: presence of daytime CS,
NYHA functional class, EF, presence of atrial fibrillation,
body mass index, age, gender, medication, serum creatinine
level, peak oxygen consumption at cardiopulmonary test,
Table 1
General characteristics and neurohormonal findings in patients with normal





Age (years) 60±14.5 66±10.2 0.01
Gender (F/M=n) 15/45 14/73 NS
ICM, n (%) 19 (32) 34 (39) NS
BMI (kg/m2) 24.6±2.9 25.1±2.6 NS
NYHA class 2.2±0.8 2.6±0.7 0.01
EF (%) 33±8.5 29±8.3 0.01
Creatinine (mg/dl) 1.08±0.3 1.25±0.4 0.01
Hb (g/dl) 13.2±1.2 12.8±1.5 NS
AF, n (%) 7 (13) 15 (18) NS
Paced rhythm, n (%) 5 (9) 7 (8) NS
ACEi/ARBs, n (%) 51 (85) 75 (86) NS
Beta-blockers, n (%) 41 (74) 59 (71) NS
Spironolactone, n (%) 31 (56) 51 (61) NS
Digoxin, n (%) 23 (43) 28 (37) NS
Diuretic, n (%) 44 (81) 65 (87) NS
Workload (Watt) 87±33 71±29 0.04
peakVO2 (mL/min/kg) 13.4±4 11.3±3.8 0.02
PETCO2 (mm Hg) 37.9±3.8 33.1±4.2 0.001
ANP (ng/L)⁎ 66.4 (18–103) 136.2 (57–230) 0.001
BNP (ng/L)⁎ 64.1 (21–202) 284 (99–510) 0.001
NT-proBNP (ng/L)⁎ 448.5 (147–1599) 2575 (814–3320) 0.001
PRA (ng/mL/h)⁎ 1.65 (0.37–5) 1.78 (0.4–4.4) NS
Aldosterone (ng/L)⁎ 156 (109–242) 150 (88–191) NS
Insulin (ng/L) 12±8.1 12±10.6 NS
Cortisol (ng/L) 168±74 164±62 NS
Epinephrine (ng/L)⁎ 31 (10–42) 35 (19–52) NS
Norepinephrine (ng/L)⁎ 438 (331–681) 588(395–939) 0.01
fT3 (ng/L) 2.4±0.1 2.3±0.1 NS
fT4 (ng/L) 12.5±0.4 13.7±0.5 NS
TSH (ng/L)⁎ 1.5 (0.68–1.8) 1.5 (0.76–2.7) NS
F: females; M: males; ICM: ischaemic cardiomyopathy; BMI: body mass
index; NYHA: New York Heart Association; EF: left ventricular ejection
fraction; AF: atrial fibrillation; ACEi: angiotensin-converting enzyme
inhibitors; ARBs: angiotensin-receptor blockers; peakVO2: peak oxygen
consumption; PETCO2: end-tidal carbon dioxide partial pressure;
ANP: atrial natriuretic peptide; BNP: brain natriuretic peptide; NT-proBNP:
N-terminal part of the pro-peptide of BNP; PRA: plasma renin activity;
fT3: free triiodothyronine; fT4: free tetraiodothyronine; TSH: thyroid
stimulating hormone; Hb: hemoglobin. Values are expressed as mean±SD
for normally distributed variables, and (⁎) as median (25th–75th percentile)
for non-normally distributed variables; % and (number of cases) are
presented for binary variables.
Table 2
Predictors at univariate and multivariate analysis of daytime CS respiration.
Odds ratio 95% C.I. P value
Univariate analysis
PETCO2 0.74 0.62–0.88 0.001
peakVO2 0.87 0.76–0.99 0.030
EF 0.95 0.91–0.99 0.013
Workload 0.98 0.96–0.99 0.018
Age 1.05 1.02–1.08 0.002
BNP 1.78 1.36–2.32 0.000
NT-proBNP 1.87 1.41–2.48 0.000
ANP 2.07 1.36–3.16 0.001
NYHA 2.10 1.29–3.42 0.003
Norepinephrine 2.36 1.25–4.46 0.008
Creatinine 4.21 1.48–12.01 0.007
Multivariate analysis
Age 1.06 1.01–1.13 0.034
NT-proBNP 1.93 1.13–3.30 0.017
CI: confidence intervals; PETCO2: end-tidal carbon dioxide partial pressure;
peakVO2: peak oxygen consumption; EF: left ventricular ejection fraction;
BNP: brain natriuretic peptide; NT-proBNP: N-terminal part of the pro-
peptide of BNP; ANP: atrial natriuretic peptide; NYHA: New York Heart
Association.
Table 3
Independent predictors at univariate and multivariate analysis of cardiac
mortality.
Hazard ratio 95% C.I. P value
Univariate analysis
peakVO2 0.83 0.70–0.98 0.027
EF 0.89 0.83–0.95 0.001
Age 1.06 1.02–1.26 0.042
NYHA 2.29 1.29–4.07 0.005
CS 3.21 1.23–8.41 0.017
BNP 3.38 1.84–6.22 0.000
NT-proBNP 4.16 2.10–8.25 0.000
AF 4.69 1.70–12.91 0.003
Multivariate analysis
NT-proBNP 2.98 1.35–6.56 0.007
PeakVO2: peak oxygen consumption; EF: left ventricular ejection fraction;
NYHA: New York Heart Association classification; CS: daytime Cheyne–
Stokes respiration; BNP: brain natriuretic peptide; NT-proBNP: N-terminal
part of the pro-peptide of BNP; AF: atrial fibrillation.
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the ventilation vs VCO2 relation in its linear part), plasma
level of BNP, NT-proBNP, norepinephrine, plasma renin
activity. Among the univariate predictors (age, ejection
fraction, atrial fibrillation, daytime CS, NYHA functional
class, serum creatinine, plasma level of BNP and NT-
proBNP), only the two with highest level of significance (EF
and plasma level of NT-proBNP were then considered for
multiple logistic regression analysis) due to the limited
number of events during follow-up [14].
Values are presented as mean±standard deviation (SD),
or median and interquartile range (for variables with non-normal distribution) and P valuesb0.05 were considered
significant.
3. Results
3.1. Prevalence of daytime breathing disorders
Daytime CS (Fig. 1) was found in 87 (59%) patients:
central hypopneas were found in 47 (32%) and central
apneas in 40 (27%) patients. All apneas and hypopneas were
identified as having a central origin (characterized by
simultaneous absence of both CO2 flow and chest/
abdominal respiratory activity).
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polysomnography, the presence of respiratory disorders at
nighttime was accurately predicted by concomitant daytime
CS (AUC 0.821, Pb0.01 at receiver operating characteristic
analysis, sensitivity 75%, specificity 75%). Patients with
significant nocturnal CS (Respiratory Disorder Index N20)
showed lower PETCO2 (31.9±5 vs 35.9±5 mm Hg,
P=0.025), higher BNP [540 (229–881) vs 159 (55–319)
ng/L, P=0.001] and NT-proBNP level [3001 (1802–3547)
vs 1238 (282–3352), Pb0.001], and worse NYHA func-
tional class (2.9±0.5 vs 2.5±0.5, P=0.003).
3.2. Clinical features, neurohormonal evaluation and
breathing abnormalities
Presence of CS was significantly associated with a more
severe clinical impairment (i.e. NYHA classification), age,
reduced EF and functional capacity, lower levels of resting
PETCO2, and renal impairment. Patients with CS presented
significantly higher plasma norepinephrine and cardiac
natriuretic peptide levels (Fig. 2), as compared to patients
with normal breathing, whereas no differences between the
two groups were found for aldosterone, PRA, epinephrine
and thyroid hormone plasma levels (Table 1).
3.3. Predictors of daytime respiratory disorders
At univariate analysis, the occurrence of daytime CS
was predicted by age, low EF, low PETCO2 level at rest,
increased level of serum creatinine, plasma norepinephrine,
ANP, BNP, and NT-proBNP (Table 2). However, at multi-
variate analysis age and plasmaNT-proBNP level were the only
independent predictors ofCS; in particular, plasmaNT-proBNP
level resulted the best predictor (AUC 0.735, Pb0.001, cut-offFig. 3. Survival among 147 patients with chronic heart failure, according to
the presence of daytime Cheyne–Stokes (CS) respiration.value 634 pg/mL, specificity 61%, sensitivity of 85%, positive
predictive value 76%, negative predictive value 73%).
3.4. Identification of risk factors for cardiac death
Median follow-up was 33 months (range 6–2000 days),
during which 17 cardiac deaths occurred (3 sudden deaths
and 14 due to congestive heart failure). Four non-cardiac
deaths were excluded from the analysis.
At the univariate analysis, the following variables were
predictive of cardiac death (Table 3): daytime CS (Fig. 3),
increased plasma level of BNP and NT-proBNP (hazard
ratios refer to a risk increase for one unit increment of their
natural logarithm), age, presence of atrial fibrillation, higher
NYHA class, EF. At the multivariate analysis, only NT-
proBNP was an independent predictor of mortality.
4. Discussion
Our study indicates that central apneas and hypopneas
occur in a high percentage of CHF patients at daytime,
despite treatment with neurohormonal antagonists. More-
over, daytime CS is associated with adrenergic activation
and overexpression of cardiac natriuretic hormones. Among
all risk factors for daytime CS at univariate analysis, the
concentration of plasma NT-proBNP was the best indepen-
dent predictor of breathing abnormalities.
The prevalence of daytime CS in the present study is
lower, as compared to earlier reports [4,8], likely due to
improvement in pharmacological treatment during the last
decade, in which beta-blockers had not been administered
systematically [15]. The pathogenesis of CS in CHF is
multifactorial and involves deregulation of negative feed-
backs secondary to enhanced chemoceptive sensitivity [16–
19], increased circulation time [18], increased filling
pressures, and decreased functional residual capacity [20].
The combination of these factors elicits an excessive
ventilatory response, lowering the difference between
circulating levels of carbon dioxide and the apneic threshold,
and thus favouring central apneas [21].
Daytime CS was significantly associated with more
severe clinical impairment, reduced left ventricular EF and
functional capacity, and lower levels of resting PETCO2. The
latter finding suggests a common pathogenesis for daytime
and nocturnal CS. Indeed, the absence of obstructive apneas
in awake patients at daytime confirms previous observations
[4,8]: in awake status there is adequate stimulation of dilator
muscles to maintain upper airway patency [22].
We also observed adrenergic activation in patients with
daytime CS (likely associated with activated chemoreflex
and CS-related oxyhemoglobin desaturation and hypoxia)
[23], which in turn may contribute to ventricular arrhythmias
and adverse prognosis [24,25], as well as increased
expression of both atrial and B-type natriuretic peptides.
Cardiac natriuretic hormone production is elicited by
increased cardiac filling pressures [11], which have been
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sympathetic activation [11], and hypoxia [27].
Male gender, atrial fibrillation, age N60 years, and
hypocapnia during wakefulness have been previously
defined as risk factors for central sleep apneas by Sin, who,
however, had not studied neurohormonal indices [13]. In our
study, we found that, in addition to age and hypocapnia,
left ventricular systolic dysfunction, NYHA class, functional
capacity, and NT-proBNP were associated with CS. The
ability of NT-proBNP level to predict daytime CS follows
previous reports on increased BNP concentration in patients
with sleep-related respiratory disorders [28,29], confirming
the close relationship between cyclical respiratory pattern,
haemodynamic overload and hypoxemic status [11,20].
Finally, our findings establish the value of resting daytime
CS in the prediction of cardiac death in CHF, paralleling the
observation byCorrà [30] on either sleep or exertional periodic
breathing, and by La Rovere [31], though only plasma level of
NT-proBNP resulted as independent prognosticator.
In a recent study by Brack et al., [32] CS during N10% of
daytime was an independent predictor of death, after adjusting
for BNP, age, and NYHA class. However, the authors enrolled
only 60 patients and employed a long-term recording device
without taking into account patient-to-patient variations in
postural changes, speech and physical daily activity.
The limited sample size and the low cardiac event rate did
not allow us to evaluate the association of daytime CS with
specific causes of cardiac death. Furthermore, a thorough
echocardiographic evaluation of left ventricular diastolic
function was available only in a portion of study population,
thus precluding its use in the overall analysis.
In conclusion, CS at daytime is easily and detectable in an
objective way in CHF patients. It is a frequent manifestation
and is associated with adrenergic activation and increased
natriuretic hormone plasma level. Daytime recording of
respiratory pattern, especially in the presence of increased
NT-proBNP levels, could discriminate patients with breath-
ing abnormalities. Further studies are necessary to evaluate
specific therapies, targeting chemoceptive feed-back and
adrenergic activation. Respiratory [33] and aerobic physical
training [34], in particular, may have the potential to improve
life quality and life expectancy in this particular subset of
CHF patients.
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